(1) Background: In COVID-19 survivors there is an increased prevalence of pulmonary fibrosis of which the underlying molecular mechanisms are poorly understood; (2) Methods: In this multicentric study, n = 12 patients who succumbed to COVID-19 due to progressive respiratory failure were assigned to an early and late group (death within ≤7 and >7 days of hospitalization, respectively) and compared to n = 11 healthy controls; mRNA and protein expression as well as biological pathway analysis were performed to gain insights into the evolution of pulmonary fibrogenesis in COVID-19; (3) Results: Median duration of hospitalization until death was 3 (IQR25-75, 3-3.75) and 14 (12.5-14) days in the early and late group, respectively. Fifty-eight out of 770 analyzed genes showed a significantly altered expression signature in COVID-19 compared to controls in a time-dependent manner. The entire study group showed an increased expression of BST2 and IL1R1, independent of hospitalization time. In the early group there was increased activity of inflammation-related genes and pathways, while fibrosis-related genes (particularly PDGFRB) and pathways dominated in the late group; (4) Conclusions: After the first week of hospitalization, there is a shift from pro-inflammatory to fibrogenic activity in severe COVID-19. IL1R1 and PDGFRB may serve as potential therapeutic targets in future studies.
- Kamp, J. C.
- Neubert, L.
- Ackermann, M.
- Stark, H.
- Werlein, C.
- Fuge, J.
- Haverich, A.
- Tzankov, A.
- Steinestel, K.
- Friemann, J.
- Boor, P.
- Junker, K.
- Hoeper, M. M.
- Welte, T.
- Laenger, F.
- Kuehnel, M. P.
- Jonigk, D. D.
Keywords
- Aged
- COVID-19/*genetics/*metabolism/mortality
- Female
- Hospital Mortality/trends
- Hospitalization
- Humans
- Lung/pathology
- Male
- Middle Aged
- Pulmonary Fibrosis/metabolism/*pathology
- Respiratory Insufficiency/pathology
- SARS-CoV-2/pathogenicity
- Covid-19
- SARS-CoV-2
- inflammation
- pulmonary fibrosis